| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_db78dfbdd06aa60a0440e651d4d1cb23 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J51-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J51-00 |
| filingDate |
2014-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f63487de820365618278d4693f1f6390
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd1fa50439f1aada633990a75ae2d524
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1df639a422b1a6aa7a14f04ced9a9cb |
| publicationDate |
2014-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2014323748-A1 |
| titleOfInvention |
Water-soluble ursodeoxycholic acid prodrugs |
| abstract |
Ursodeoxycholic acid (UDCA) is a bile acid with demonstrated anti-apoptotic activity in both in vitro and in vivo models. Water-soluble prodrugs of UDCA for use in indications where intravenous administration of UDCA may be preferable, such as reducing damage from stroke or acute kidney injury, are disclosed. The disclosed prodrugs showed significant anti-apoptotic activity in a series of in vitro assays. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3890745-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102106943-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2022504638-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020117945-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11072630-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7203964-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190094671-A |
| priorityDate |
2013-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |